Dasatinib promotes apoptosis of cutaneous squamous carcinoma cells by regulating activation of ERK1/2.
Department of Dermatology, University of Turku and Turku University Hospital, Turku, Finland.|MediCity Research Laboratory, University of Turku, Turku, Finland.
Mehdi
M
Farshchian
Department of Dermatology, University of Turku and Turku University Hospital, Turku, Finland.|MediCity Research Laboratory, University of Turku, Turku, Finland.
Liisa
L
Nissinen
Department of Otorhinolaryngology - Head and Neck Surgery, University of Turku and Turku University Hospital, Turku, Finland.
Reidar
R
Grénman
Department of Dermatology, University of Turku and Turku University Hospital, Turku, Finland.|MediCity Research Laboratory, University of Turku, Turku, Finland.
Veli-Matti
VM
Kähäri
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000378:metabolism; D045744:Cell Line, Tumor; D000069439:Dasatinib / Q000494:pharmacology / Q000627:therapeutic use*; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D020935:MAP Kinase Signaling System; D036183:Receptor, EphB2 / Q000378:metabolism*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D000970:Antineoplastic Agents; C586310:EPHB2 protein, human; D036183:Receptor, EphB2; D000069439:Dasatinib

ERK
; EphB2; apoptosis; dasatinib; squamous cell carcinoma